Morgan Stanley Cuts Zoetis (NYSE:ZTS) Price Target to $175.00

by · The Cerbat Gem

Zoetis (NYSE:ZTS – Get Free Report) had its price target reduced by stock analysts at Morgan Stanley from $211.00 to $175.00 in a report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 46.52% from the company’s current price.

A number of other research analysts have also recently weighed in on the stock. Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Stifel Nicolaus set a $140.00 price objective on Zoetis in a report on Tuesday, November 4th. Finally, Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $182.50.

Read Our Latest Stock Analysis on ZTS

Zoetis Stock Performance

Shares of ZTS stock traded down $0.80 during mid-day trading on Monday, hitting $119.44. The stock had a trading volume of 2,509,481 shares, compared to its average volume of 3,118,774. The firm has a market cap of $52.64 billion, a PE ratio of 20.56, a PEG ratio of 2.31 and a beta of 0.90. The company’s 50-day simple moving average is $144.21 and its 200-day simple moving average is $152.63. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis has a fifty-two week low of $117.26 and a fifty-two week high of $181.85.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis will post 6.07 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Westerkirk Capital Inc. grew its stake in Zoetis by 27.3% in the 3rd quarter. Westerkirk Capital Inc. now owns 42,900 shares of the company’s stock valued at $6,277,000 after buying an additional 9,200 shares during the last quarter. Premier Fund Managers Ltd grew its position in shares of Zoetis by 4.5% in the third quarter. Premier Fund Managers Ltd now owns 62,558 shares of the company’s stock valued at $8,952,000 after purchasing an additional 2,700 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ grew its position in shares of Zoetis by 1.3% in the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 328,175 shares of the company’s stock valued at $48,019,000 after purchasing an additional 4,116 shares during the last quarter. Advyzon Investment Management LLC increased its stake in shares of Zoetis by 50.9% in the third quarter. Advyzon Investment Management LLC now owns 2,083 shares of the company’s stock worth $305,000 after purchasing an additional 703 shares during the period. Finally, Rossby Financial LCC lifted its position in shares of Zoetis by 29.7% during the 3rd quarter. Rossby Financial LCC now owns 7,610 shares of the company’s stock worth $1,118,000 after purchasing an additional 1,744 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading